Sumitovant Biopharma Ltd. has officially acquired Myovant Sciences Ltd. The deal was originally announced October 23, 2022. Sumitovant has acquired all outstanding shares of Myovant not already owned by Sumitovant in an all-cash deal with a total transaction value of almost $1.7 billion. "We are excited to have officially completed our acquisition of Myovant and look forward to working together to address unmet needs in women's health and prostate cancer," said Myrtle Potter, CEO of Sumitovant. "By combining our unique expertise, platforms and resources, we will be better positioned to drive the growth of Myovant's products and accelerate the development of our robust combined pipeline." Hiroshi Nomura, CEO of Sumitomo Pharma said: "I am confident that bringing together the capabilities and strengths of Sumitovant and Myovant will best position us to continue delivering innovative therapies to patients sooner and accelerate the potential opportunities for ORGOVYX and MYFEMBREE." "I look forward to all we will be able to achieve with the support of Sumitovant and Sumitomo Pharma to expand the impact of our differentiated therapies and advance our clinical programs," said David Marek, CEO of Myovant. "We remain steadfast in our commitment to advance life-changing medicine and health equity for the patient communities we serve."
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!